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We aimed to identify recipient, donor and transplant
risk factors associated with graft failure and patient
mortality following donation after cardiac death (DCD)
liver transplantation. These estimates were derived
from Scientific Registry of Transplant Recipients data
from all US liver-only DCD recipients between Septem-
ber 1, 2001 and April 30, 2009 (n = 1567) and Cox re-
gression techniques. Three years post-DCD liver trans-
plant, 64.9% of recipients were alive with functioning
grafts, 13.6% required retransplant and 21.6% died.
Significant recipient factors predictive of graft failure
included: age ≥ 55 years, male sex, African–American
race, HCV positivity, metabolic liver disorder, trans-
plant MELD ≥ 35, hospitalization at transplant and the
need for life support at transplant (all, p ≤ 0.05). Donor
characteristics included age ≥ 50 years and weight
>100 kg (all, p ≤ 0.005). Each hour increase in cold is-
chemia time (CIT) was associated with 6% higher graft
failure rate (HR 1.06, p < 0.001). Donor warm ischemia
time ≥ 35 min significantly increased graft failure rates
(HR 1.84, p = 0.002). Recipient predictors of mortal-
ity were age ≥ 55 years, hospitalization at transplant
and retransplantation (all, p ≤ 0.006). Donor weight
>100 kg and CIT also increased patient mortality (all,
p ≤ 0.035). These findings are useful for transplant sur-
geons creating DCD liver acceptance protocols.
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Introduction
The continued critical shortage of donor liver allografts has
prompted innovative strategies to increase the donor pool.
In addition to the proliferation of organ donor recruitment
initiatives, transplant providers have been encouraged by
the Institute of Medicine and the Health Resources and
Services Administration (HRSA) to use grafts from higher
risk donors to decrease the burden of a growing waiting
list (1–3). The utilization of liver allografts from donors after
cardiac death (DCD) has increased over the last decade,
and now comprises more than 5% of all liver transplants
(4).
It is well known that outcomes after DCD liver trans-
plantation are inferior to transplantation using livers from
brain dead donors (4–19), and these differences have
been ascribed to organ injury related to the pathophys-
iology of donor death and subsequent graft-related mor-
bidity (6,8,10,13,14,19). The inferior graft survival related
to DCD liver transplantation could potentially be miti-
gated by recognizing the presence of extraordinary donor
risk factors and by optimizing donor–recipient matching.
Several authors have identified ischemic cholangiopathy
as a main driver of inferior DCD liver graft outcomes
(6,8,10,13,14,19). Clinical decision-making in the donor se-
lection process would be enhanced by knowing whether
risk factors for ischemic cholangiopathy also predict graft
failure and/or death following DCD liver transplantation.
This would enable transplant surgeons to determine de-
grees of ‘high risk’ for a given transplant candidate–donor
pair, and provide for a more informed prediction of a recip-
ient’s clinical course.
The intent of this study was to determine recipient and
donor risk factors associated with inferior DCD outcomes
using comprehensive data from the Scientific Registry of
Transplant Recipients (SRTR). Additionally, we sought to
better understand posttransplant outcomes following DCD
liver transplantation including retransplantation and mortal-
ity rates. We hypothesized that factors demonstrated in
prior single-center studies to be associated with ischemic
cholangiopathy including donor weight, donor age and cold
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ischemia time (CIT) would also be associated with graft fail-
ure and posttransplant mortality.
Methods
Using liver transplant recipient and donor data from the SRTR, a retrospec-
tive cohort was constructed of DCD liver transplant recipients who received
liver-only grafts from September 1, 2001 to April 30, 2009. All patient-level
transplant candidate, recipient and donor data are submitted by all trans-
plant centers and organ procurement organizations to the Organ Procure-
ment and Transplantation Network (OPTN), which subsequently transfers
these data to the SRTR. The SRTR uses several methods to ascertain and
verify recipient outcomes by cross validating against other data sources,
such as the Social Security Death Master File for candidate and recipient
mortality (20,21). SRTR data are the most comprehensive national data on
candidate, recipient and donor demographics, comorbidities, disease pro-
gression, clinical risk factors and posttransplant outcomes including graft
failure and recipient death (21).
Predictors of inferior DCD outcomes
We used a cumulative incidence function to ascertain the competing risk
rates of various post-DCD liver transplant outcomes over time, including
the proportions alive with a functioning graft, retransplanted and dead. Mul-
tivariable Cox proportional hazards models were used to determine donor,
recipient and transplant predictors of inferior DCD outcomes, with separate
models for graft failure and for posttransplant mortality. Graft failure was
defined as the earlier of retransplantation or death. In the mortality model,
retransplantation was treated as a time-varying covariate, meaning the ef-
fect of a repeat transplant was not exerted on post-DCD liver transplant
mortality until it occurred. Follow-up time at risk was censored at the end
of follow-up (October 31, 2009) in both models. All patients had at least
6 months of follow-up. For each model, we evaluated all clinically relevant
covariates available in the SRTR data, and focused particularly on those that
were predictive of ischemic cholangiopathy in previous single center stud-
ies (6,16,22,23). Donor variables tested in the models included donor age,
race, body mass index, weight and donor cause of death. Investigated re-
cipient characteristics included age, race, sex, medical condition, prior liver
transplantation, diagnosis, preexisting candidate malignancy, diabetes, prior
abdominal surgery and portal vein thrombosis. Transplant characteristics in-
cluded local versus shared donor, partial or split liver, ABO compatibility,
donor warm ischemia time (DWIT)(from cessation of cardiopulmonary sup-
port to in situ cold perfusion) and CIT. In order to explore the effects of warm
and CIT, the functional form of each of these variables was determined by
assessing lowess plots of martingale residuals and statistical significance of
the covariates in the graft failure model. Various categorizations, cut-points
and splines were tested during the model building process. Indicators were
used for missing data, as fewer than 10% of the total data across all vari-
ables were missing.
Additional analyses focused on the potential association of interactions
among risk factors for ischemic cholangiopathy with rates of graft failure
and patient death. Chan et al. (22) have previously shown that older donor
age, high donor weight and long ischemia times were associated with the
development of ischemic cholangiopathy. Interaction terms were created
by combining the individual covariate effects that were thought to have the
most clinical impact on ischemic cholangiopathy. These terms were then
tested in the graft loss and survival models.
This study was approved by the US HRSA SRTR project officer. HRSA
has determined that this study satisfies the criteria for the nstitutional Re-
view Board exemption described in the ‘Public Benefit and Service Pro-
gram’provisions of 45 Code of Federal Regulations 46.101(b)(5) and HRSA
Circular 03. All statistical analyses were performed using SAS v9.2 (SAS
Institute, Cary, NC, USA). Statistical significance was defined by p < 0.05.
Results
There were 1567 DCD liver transplants identified over the
time period. More than 80% of patients had greater than
1 year of follow-up, with minimum follow-up of 182 days.
The demographic and clinical characteristics of DCD liver
transplant recipients and donors are displayed in Table 1.
Nearly 5% of DCD liver transplant recipients had previ-
ously undergone a liver transplant. More than 20% of DCD
liver transplant recipients were hospitalized at the time of
transplant. Approximately 5% of DCD liver recipients were
listed as Status 1. The average age of DCD liver donors
was 35.2 ± 15.4 years and two-thirds were male. Average
donor body weight was 77.3 ± 20.8 kg. Traumatic injury
was the most common cause of death. Mean CIT was
7.5 ± 3.7 h, and mean DWIT was 16 min. More than 60%
of the DCD livers were procured locally. Only 2.5% of the
DCD donors were uncontrolled.
In the 3 years following DCD liver transplant, there was a
substantial incidence of graft failure, retransplantation and
mortality (Figure 1). The cumulative probability of being
alive with a functioning DCD graft at 3 years was higher
than 64%. However, the probability of death was 21.6%
within 3 years, with the highest rate during the first year.
Relisting occurred in 19.9% of DCD liver transplant recip-
ients (n = 312), at a median of 73.5 days following trans-
plant (interquartile range 6–209 days). Median lab Model
for End-Stage Liver Disease (MELD) at relisting was 21
(interquartile range 16–29). However, the cumulative prob-
ability of retransplantation was only 13.6% by 3 years, likely
reflecting attrition of relisted candidates due to death or low
transplant rates. The majority of retransplants occurred in
the first few months following DCD liver transplantation.
Several recipient, donor and transplant factors were identi-
fied as predictors of graft failure following DCD liver trans-
plantation (Table 2). Recipients ≥ age 55 years had a sig-
nificant 26% higher adjusted graft failure rate compared
to recipients age 18–55 years. Pediatric recipients (less
than 18 years old) had a lower graft failure rate (hazard
ratio [HR] 0.33; p = 0.04). Female sex was significantly
protective from graft failure, whereas African–American
race was associated with a 38% higher graft failure rate
compared to white race. Compared to recipients with
noncholestatic liver disorders, those with metabolic liver
diseases had a twofold higher adjusted risk of graft fail-
ure. Previous liver transplantation trended toward a 45%
higher DCD liver graft failure rate compared to those who
underwent primary liver transplant (HR 1.45, p = 0.063).
Although Status 1 medical urgency was not significantly as-
sociated with graft failure, other metrics of disease sever-
ity had notable effects. Those with MELD scores greater
than 35 at transplant had a significant 47% higher graft
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Table 1: Recipient, donor and transplant characteristics for 1567 DCD liver transplants
Recipient characteristics
Mean SD
Age (mean)(SD) 52.9 11.4
BMI (kg/m2) 28.1 5.8
Lab MELD/PELD at transplant 171 13–242
Frequency Percent
Male sex 1062 67.8




Recipient diagnosis Noncholestatic 1039 66.3





Previous liver transplant 75 4.8
Status 1 medical urgency 70 4.5
Medical condition at transplant Ambulatory 1193 76.1
Non-ICU hospitalized 210 13.4
ICU hospitalized 164 10.5
Donor characteristics
Mean SD
Age (mean)(SD) 35.2 15.4
Weight (kg) 77.3 20.8
Frequency Percent
Male sex 1034 66.0








Uncontrolled DCD donor 39 2.5
Transplant characteristics
Mean SD
Cold ischemia time (h) 7.5 3.7
Donor warm ischemia time (mins) 16.1 9.2
Frequency Percent
Donor location Shared 550 35.1
Local 1017 64.9
ABO incompatible 10 0.6
1Median MELD score.
2Interquartile range of MELD scores. PELD = Pediatric End-Stage Liver Disease.
failure rate than those with MELD scores 15–25. Hospi-
talization and the requirement of life support, respectively,
were also significant independent predictors of graft fail-
ure. Older donor age (>50 years) was associated with a
39%–88% higher adjusted risk of graft failure compared
to donors age 18–50 years (donor age 50–60 years, HR
1.39, p = 0.0047; donor age ≥60 years, HR 1.88, p =
0.0011). Donor body weight greater than 100 kg was asso-
ciated with a significant 56% higher adjusted risk of graft
failure compared to those less than 100 kg. Donor cause
of death was not significantly associated with risk of graft
failure.
DWIT and CIT were independently associated with graft
failure. The distribution of DWIT is displayed in Figure 2.
As shown in Figure 3, DCD liver grafts with DWIT 35 min
or greater (3.8% of cases) had a significant 1.8-fold higher
graft loss rate compared to those with DWIT less than
15 min (p = 0.0028). Graft failure rates were not signifi-
cantly different for those with DWIT of 15–35 min com-
pared to those less than 15 min. Each hour of CIT was asso-
ciated with a 6% increase in the relative rate of graft failure
when analyzed continuously (p < 0.001). When analyzed
categorically, even moderate CIT (6–10 h) was associated
with a significant 64% higher graft failure risk (compared to
2514 American Journal of Transplantation 2010; 10: 2512–2519
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Figure 1: Cumulative incidence of post-DCD liver transplant
outcomes. Three years after undergoing DCD liver transplanta-
tion, nearly 65% of recipients were alive with a functioning graft.
However, more than 20% of these recipients were dead at 3 years,
and 13.6% required a subsequent liver transplant.
those less than 6 h). Compared to those with CIT less than
6 h, CITs greater than 10 h (16% of cases) were associated
with at least a twofold risk of graft failure, but this relative
risk approached a fourfold increase when CIT was greater
than 13 h (4% of cases) (HR 3.84, p < 0.0001). Missing
CIT, which may be a proxy for longer CITs, was also as-
sociated with significantly higher adjusted graft failure and
patient mortality rates (Table 2). Local and shared organs
did not have significantly different risks of graft failure after
adjusting for CIT time.
Several recipient, donor and transplant factors were pre-
dictive of posttransplant mortality (Table 3). Older recipient
age (≥55 years) was associated with a significant 60%
higher mortality risk compared to those aged 18–55 years.
Retransplantation was associated with a 2.4-fold higher
mortality rate compared to those whose grafts remained
functional following the index DCD transplant. Notably,
several of the recipient factors associated with graft failure
in Table 2 were not significant predictors of mortality after
adjusting for retransplantation. Patients who were hospi-
talized at the time of DCD transplant had a 48% higher
risk of dying compared to the ambulatory liver transplant
recipients. Compared to low MELD scores (<15), higher
MELD scores were not significantly associated with post-
transplant mortality. Status 1 medical urgency was not pre-
dictive of posttransplant mortality.
Previously identified risk factors for ischemic cholangiopa-
thy (donor age, donor weight and CIT) were highly asso-
ciated with poor outcomes following DCD liver transplan-
tation, which prompted testing of interactions between
these terms in graft failure and mortality models. Several
interaction terms between advanced donor age (age >60
years), long CIT (>10 h) and donor body weight (>100 kg)
were created and their effects on graft failure and patient
mortality were modeled. These interactions were not sig-
nificantly associated with graft failure or mortality (data not
shown).
Discussion
As utilization of DCD liver grafts has increased over the
past decade, outcomes following transplantation of these
grafts have been compared to outcomes of grafts from
brain dead donors (4,8,10–12,24). These comparisons are
important, but they do not help transplant providers un-
derstand which DCD liver grafts may be associated with
acceptable long-term outcomes and which may not. Few
studies have attempted to identify risk factors for poor out-
comes among the DCD liver transplant population (15,16).
We have demonstrated that a number of recipient, donor
and transplant factors are independently associated with
graft failure and post-DCD transplant mortality. Factors that
have been previously identified to be associated with is-
chemic cholangiopathy, including donor age, donor weight
and CIT were independently associated with post-DCD
transplant graft failure, but, of these factors, only donor
weight and CIT were also shown to affect post-DCD trans-
plant mortality after adjusting for retransplantation.
Authors from several single-center studies have described
outcomes following DCD liver transplantation, but these
smaller cohorts are generally underpowered to demon-
strate significant differences in patient mortality and graft
failure risks among DCD recipients. These studies are also
difficult to generalize, because individualized center prac-
tices and allocation-related issues may affect donor selec-
tion (6,8,9,11,14,17,18). Further, these studies do not pro-
vide transplant surgeons with information on longer term
prognosis. Lee et al. (15) and Mateo et al. (16) previously
studied retrospective cohorts derived from OPTN data to
create DCD liver risk profiles. Each was driven by trans-
plant factors including CIT greater than 10 h, donor factors
including age over 60 years and recipient factors including
the need for life support at transplant and previous liver
transplant. Our study improves upon the existing literature
using an updated cohort of 1567 patients with at least
6 months of posttransplant follow-up. Growing utilization
of DCD liver allografts and increasing scrutiny of transplant
outcomes warrants the use of robust clinical data from
clinical registries to assist providers in assessing individ-
ual patient risk. We have demonstrated that more than
one-third of DCD liver transplant recipients die or require
a subsequent liver transplant 3 years after the initial trans-
plant. This may improve the informed consent process,
and help assist providers in providing recommendations
to patients given their individual needs and the particular
organ availability constraints locally.
The selective utilization of DCD liver grafts by transplant
surgeons is based on several factors, which involve judg-
ing donor quality before and after organ procurement. Our
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Table 2: Predictors of graft failure following DCD liver transplantation1
Variable Hazard ratio 95% CI p-Value
Recipient characteristics
Age at transplant <18 years (reference 18–55
years)
0.33 0.11 0.95 0.040
≥55 years (reference 18–55
years)
1.26 1.05 1.52 0.014
Sex Female (reference male) 0.73 0.59 0.91 0.004
Race African American (reference
white)
1.38 1.02 1.87 0.038
Diagnosis Metabolic disorders (reference
noncholestatic cirrhosis)
2.13 1.31 3.47 0.003
MELD Score ≥35 (reference 15–25) 1.47 1.00 2.16 0.048
Hospitalization status ICU or non-ICU hospitalization at
transplant (reference
ambulatory)
1.39 1.09 1.78 0.008
Medical condition at transplant On life support (reference no life
support)
1.46 1.01 2.13 0.045
Hepatitis C virus serology Positive (reference no, unknown,
missing)
1.23 1.01 1.51 0.041
Donor characteristics
Donor age <18 years (reference 18–50
years)
0.71 0.50 1.00 0.0498
50–60 years (reference 18–50
years)
1.39 1.11 1.75 0.0047
≥60 years (reference 18–50
years)
1.88 1.29 2.74 0.0011
Donor weight >100 kg 1.56 1.20 2.04 0.0010
Transplant characteristics
Donor warm ischemia time2 ≥35 mins (reference <35 mins) 1.84 1.23 2.74 0.0028
Cold ischemia time 6–10 h (reference <6 h) 1.64 1.29 2.08 <0.0001
10–13 h (reference <6 h) 2.04 1.50 2.78 <0.0001
≥13 h (reference <6 h) 3.84 2.57 5.74 <0.0001
Missing (reference <6 h)3 2.42 1.77 3.30 <0.0001
1Also adjusted for: donor cause of death, race, sex and height, recipient BMI, diabetes, diagnosis, status 1/1A/1B, on dialysis, previous
liver transplant, previous malignancy, previous abdominal surgery, history of portal vein thrombosis at transplant, HBV serology and ABO
compatibility.
2Warm ischemia time was missing in 8.6% of DCD liver recipients.
3Cold ischemia time was missing in 10.3% of DCD liver recipients.
Figure 2: Donor warm ischemia time
distribution among 1567 DCD liver
transplant recipients. Donor warm is-
chemia time, defined as the time from
cessation of cardiopulmonary support
to aortic cannulation and core cooling,
was widely dispersed among all DCD
liver transplant recipients. The distribu-
tion is somewhat leftward shifted, ow-
ing to the utilization of some grafts with
very long donor warm ischemia times.
Notably, 3.8% of DCD liver transplant
recipients had grafts implanted with
donor warm ischemia times greater
than 35 min.
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Figure 3: The effect of donor warm
ischemia time on graft failure fol-
lowing DCD liver transplantation.
Using a multivariable Cox regression ap-
proach, we determined that donor warm
ischemia time has a significant effect
on graft failure risk, defined as requir-
ing retransplantation or death. After sev-
eral sensitivity analyses, donor warm is-
chemia time of 35 min or greater was
identified as a threshold associated with
a significantly increased adjusted rate of
graft failure.
study provides a framework from which to judge clini-
cal risk of a DCD liver at the time of organ acceptance.
Our data suggest that DCD liver grafts from older, heavier
donors with long CIT should be used with caution, given
the increased graft failure risk associated with these fac-
tors. DWIT was also highly associated with graft failure.
However, the relationship between DWIT and graft fail-
ure was nonlinear. Instead, an apparent threshold effect
was noted at 35 min. We speculate that this may reflect
selective discard of poor quality organs with lower warm
ischemia time on the basis of surgical judgment, and only
limited use (less than 5% of cases) of organs with DWIT
longer than 35 min. The duration of DWIT is weighed heav-
ily in the decision to use a DCD liver; its effects are influ-
enced by donor hemodynamics during the agonal phase
and by variations in DCD organ recovery practices. Our
models are limited by the level of detail available in the
DCD donor data submitted to the OPTN. Future analyses
will benefit from additional data now being collected dur-
ing the agonal period, including serial hemodynamic mea-
surements at regular intervals and other physiological pa-
rameters (25). The inability to account for variations from
standard DCD organ procurement practices is a confound-
ing factor (26), thus reducing the direct applicability of our
observational data analyses to individual organ donation
events. However, the results presented here may help





Age at transplant ≥55 years (reference = age 18–55 years) 1.60 1.28 1.99 <0.0001
Retransplant2 2.35 1.75 3.17 <0.0001
Hospitalization status ICU or non-ICU hospitalization at 1.48 1.12 1.97 0.006
transplant (reference ambulatory)
Donor characteristics
Donor weight >100 kg 1.39 1.02 1.89 0.035
Transplant characteristics
Cold ischemia time3 6–10 h (reference <6 h) 1.49 1.12 1.98 0.0058
10–13 h (reference <6 h) 1.95 1.36 2.78 0.0003
≥13 h (reference <6 h) 2.26 1.39 3.69 0.0011
Missing (reference <6 h) 2.02 1.39 2.92 0.0002
1Also adjusted for: donor cause of death, race, sex and height, recipient race, sex, BMI, diabetes, status 1/1A/1B, lab MELD score at
transplant, on dialysis, previous malignancy, previous abdominal surgery, recipient BMI, history of portal vein thrombosis at transplant,
HBV serology, HCV serology, ABO compatibility, local/shared organ and warm ischemia time.
2Time-varying covariate.
3Cold ischemia time was missing in 10.3% of DCD liver recipients.
American Journal of Transplantation 2010; 10: 2512–2519 2517
Mathur et al.
surgeons create better evidence-based DCD acceptance
protocols and assist in informing patients of the risks as-
sociated with specific types of DCD liver grafts.
MELD-based liver allocation has facilitated improved clini-
cal decision-making in liver transplantation, but the MELD
system was not specifically designed to predict posttrans-
plant outcomes (27–31). Nonetheless, in our mortality
model, DCD liver recipients with MELD scores greater
than 35 at transplant were at significantly higher graft fail-
ure risk than those with MELD scores of 15–25. We did not
see a similar relationship between MELD and the risk of
posttransplant mortality. Any causal relationship between
higher recipient MELD at transplant and inferior outcomes
among DCD liver transplants could not be derived from our
current study, but deserves scrutiny in future work.
The development of ischemic biliary strictures is a major
source of morbidity after DCD liver transplant. This injury is
very difficult to treat, and although endoscopic and percu-
taneous biliary drainage may provide symptomatic relief,
the underlying pathology in some cases is progressive,
ultimately requiring retransplantation or leading to death.
We could not calculate the attributable risk of ischemic
cholangiopathy in relation to long-term graft or patient out-
come, because neither its definition nor time of onset is
uniform or reported to the OPTN. Factors associated with
ischemic cholangiopathy including older donor age, high
donor weight, CIT and DWIT were significant predictors of
graft failure in our study (16). Further studies are clearly
needed to identify clinical tools that ameliorate the risk of
biliary injury in DCD grafts, such as improvements in or-
gan preservation. Progressive DCD liver graft dysfunction
causes significant patient morbidity and leads to substan-
tial clinical resource utilization, which may warrant relisting
for transplant. Retransplantation was associated with sig-
nificantly higher mortality risk compared to those whose
original grafts survived, but further study is warranted to
determine whether modification of allocation rules is nec-
essary to increase access to retransplantation for those
with failing DCD liver grafts. Retransplantation of patients
with ischemic cholangiopathy and progressive graft dys-
function and/or cholangitis may be challenging, depending
on their waiting list priority as measured by lab MELD.
Clearly, further clinical and policy investigations are nec-
essary to reduce the incidence and improve outcomes for
recipients who develop ischemic cholangiopathy after DCD
liver transplant.
Our study has some additional limitations, primarily related
to the depth and quality of data available to the SRTR. We
observed a significant association between longer DWIT
and worse graft outcome. However, this variable is subject
to bias related to variation in the practice of DCD organ
recovery and volatile hemodynamics following cessation
of cardiopulmonary support (26). An additional weakness
is related to missing data, as patients who had no recorded
CIT had significantly higher risks of graft failure and patient
death. Precise interpretation of this finding is impossible.
It is possible that the true values for missing CITs are very
long, and may be a broader marker of poor organ quality
resulting in delayed placement by the organ procurement
organization. Alternatively, missing data may be a surrogate
for the quality of patient care. Both of these explanations
must be considered speculative (32).
In summary, DCD liver transplantation remains an impor-
tant effort to expand organ availability with 3-year graft sur-
vival rates greater than 60%. However, donor, recipient and
transplant factors all may be associated with incrementally
poorer outcomes following DCD liver transplantation. Fur-
ther study is needed to refine our understanding of these
risk factors, and the events that define the impact of DWIT,
such that donor and recipient selection may be modified in
the hopes of allowing optimal selective use of livers from
DCD donors.
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